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Abstract
Lupus is one of the complex autoimmune disease, which is difficult to diagnose 
and consists of few subtypes that are required to be classified. During our clini-
cal work, we found out that the dermoscopy can be of great benefit to diagnose 
discoid lupus erythematosus (DLE). The histopathological examination is very 
important to confirm the diagnosis. The cases of infant LE patients, may derive 
the autoimmune antibodies from their mothers in order to diagnose the neonatal 
lupus erythematosus. Thus, it is very important to examine the antibodies of the 
mother, who may also be a subclinical LE patient and need continuous follow-ups 
or even treatment managements. Here, we present the cases of lupus with particular 
characteristics including linear cutaneous lupus erythematosus, DLE, and neonatal 
lupus erythematosus.
Keywords: lupus erythematosus, linear erythematous atrophic patch,  
neonatal lupus erythematosus, discoid lupus erythematosus, dermoscopy
1. Introduction
Systemic lupus erythematosus is a chronic, relapsing, inflammatory, and often 
febrile multisystemic disorder of the connective tissue, characterized principally by 
involvement of the skin, joints, kidneys, and serosal membranes. The word lupus 
means wolf in Latin, as the destructive injuries the disease caused brought to mind 
the bites of this animal [1, 2]. The earliest usage of the term lupus in the English lit-
erature is in the tenth century biography of St. Martin, written in 963 AD. However, 
the modern period of our understanding of this disease began in 1948, when Mayo 
Clinic hematologist Malcolm Hargraves [3] discovered the LE cell.
Lupus is all known as a spectrum disease, the symptoms between patients 
varies from mild to severe and can be divided into systemic lupus erythematosus 
(SLE) and cutaneous lupus erythematosus (CLE). CLE includes three subsets 
of LE-specific skin diseases: acute cutaneous lupus erythematosus (ACLE), 
subacute cutaneous lupus erythematosus (SCLE), and chronic cutaneous lupus 
erythematosus (CCLE). CCLE encompasses discoid lupus erythematosus (DLE), 
lupus erythematosus tumidus (LE tumidus), lupus profundus (also known as 
lupus panniculitis), chilblain lupus erythematosus (chilblain LE), and lichenoid 
cutaneous lupus erythematosus-lichen planus overlap syndrome  
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(LE-LP overlap syndrome). CLE can occur as a manifestation of SLE or indepen-
dent of SLE. Patients with SLE may also develop a variety of LE-nonspecific skin 
diseases, cutaneous disorders that lack histologic features of LE, but occur with 
increased frequency in patients with SLE.
On diagnosing a systemic lupus erythematosus, we have several groups of 
diagnostic criteria. The major positive characteristics such as swollen joints, but-
terfly rash on the face, photo-sensitivity, or hair loss helps in the confirmation of 
the diagnosis. The laboratory examinations such as double-stranded DNA antibody 
(ds-DNA), anti-nuclear antibody (ANA) and other autoimmune antibodies are 
regarded as the highest level of consideration.
A systematic approach should be taken because of the diversity and complexity 
of clinical and laboratory manifestations [4–6]. Clinical manifestations may be due 
to one or any combination of the following: disease activity from active inflamma-
tion or thrombosis, acute drug toxicity, chronic damage due to the effects of the 
disease or its treatment (such as lung fibrosis or atherosclerosis), or comorbidity 
(e.g., infection). It is important to take a detailed history and to perform a clinical 
examination, including vital signs and urinalysis, to establish the likely differen-
tial diagnoses and then to organize the relevant investigations, depending on the 
circumstances. In addition, when assessing disease activity with a view to planning 
treatment, it is necessary to determine the circumstances that may have led to a 
lupus flare (such as exposure to sunlight, infection, hormonal changes, or previous 
disease-related therapeutic change) as this will guide further investigation, treat-
ment change and disease monitoring required thereafter.
However, there are many subtypes of lupus, such as discoid lupus erythematosus 
and neonatal lupus erythematosus that does not follow the standard diagnostic cri-
terion. Here, we present four instructive case studies of lupus. We hope this chapter 
will enlighten the perspective on lupus.
2. Brief overview of dermoscopy
Dermoscopy is a noninvasive method that allows the in vivo evaluation of colors 
and microstructures of the epidermis. It has been widely studied in differentiating 
benign and malignant skin lesions. With dermoscopy the diagnostician’s sensitivity 
to diagnose melanoma is 90% compared to 74% when the technique is not used. 
It helps to avoid unnecessary surgery and give dermatologist more perspectives to 
plan the surgery. The diagnose and differential diagnosis of hair and nail diseases 
are also getting advanced benefits since application of dermoscopy. And now, 
dermoscopy is expanding its role as a tool for the evaluation of inflammatory skin 
conditions such as psoriasis, lichen planus and lupus.
3. Case presentations
3.1  Case 1. Linear cutaneous lupus erythematosus distributed along a reverse 
Blaschko lines
A 15-year-old female presented with itching linear erythema on the left forehead 
for 3 years. The erythema extended gradually to the scalp and the left upper eyelid, 
distributed in a linear pattern over time [7]. The patient was healthy except the 
lesion. Family history was negative. Physical examination showed that she was in 
good conditions. Dermatological examinations showed a longitudinal erythema on 
the left side of the hairline, forehead and left upper eyelid distributed in “S” shape 
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pattern. The surface of forehead lesion showed obvious atrophy, telangiectasis and 
adhesive scales (Figure 1a).
Laboratory examination of routine blood and urine test results, liver and renal 
function were all normal. Serum IgG, IgA, IgM, IgE, rheumatoid factor (RF), CIC, 
ANA, Anti-ds-DNA, Anti-RNP, Anti-SM, SSA, SSB, Anti-SCL-70 and Anti-Jo-1 
antibody were within normal limits. Complement 3 (C3) 0.749 g/L (normal value, 
0.785–1.52 g/L), Complement 4 (C4) 0.121 g/L (normal value, 0.145–0.36 g/L). 
Histological examination showed follicular keratotic plugging, vacuolar alteration 
of the basal cell layer, thickening of the basement membrane, perivascular infiltra-
tion of lymphocytes in the dermis (Figure 1b and c), which led to the diagnosis of 
linear cutaneous lupus erythematosus.
She was treated with compound glycyrrhizin tablets (two tablets three times 
a day, containing 150 mg glycyrrhizin, 210 mg monoammonium glycyrrhizinate, 
150 mg aminoacetic acid, and 150 mg methionine), hydroxychloroquine tablets 
(200 mg once a day), and topical application of 0.1% tacrolimus ointment (twice a 
day). After half a year of follow-up, the skin lesion was improved with no tendency 
of systemic involvement.
3.2 Case 2. Dermoscopic presentation of DLE
A 38-year-old male with rapidly progressing papules demonstrating the 
features of acne on the left prefrontal region accompanied with tenderness for 
2 months (Figure 2a). The patient had been diagnosed as epifolliculitis and treated 
with mupirocin cream for 1 month with no improvement. Physical examina-
tion revealed erythema, papules, callus shells, and plaques on his left prefrontal 
region. The results of blood routine and serum immunological examinations were 
normal. The specificity examinations including circulating immune complex, C3 
and C4, antinuclear antibodies, double-stranded DNA antibody (ds-DNA), SSA/
Ro antibody, and SSB/La antibody showed no any significant findings. However, 
dermoscopy of the lesions showed that the erythematous base was interrupted by a 
prominent keratinization around the hair follicles and follicular keratotic plugging 
(Figure 2b) [8]. It clued for differentiating atypical discoid lupus erythematosus 
from epifolliculitis with dermoscopy, and dermoscopy guided biopsy yielded a 
definitive histopathological diagnosis of the case. Histopathological evaluation 
of the lesions revealed dilated follicular openings filled with cornified material, 
follicular plugging, a necrosed part of the stratum basale, and inflammatory cell 
infiltration of the perifollicular and shallow dermal layers, which indicated discoid 
Figure 1. 
(a) A longitudinal erythema on the left side of the hairline, forehead and left upper eyelid distributed in an 
“S” pattern. The forehead lesion showed obvious atrophy, telangiectasis and adhesive scales. (b) Histological 
examination showed epidermal atrophy, follicular plugging, and the perivascular infiltration of lymphocytes in 
the dermis (HE stain × 100). (c) Vacuolar alteration in the basal layer of the epidermis, and thickening of the 
basement membrane (HE stain × 400).
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lupus erythematosus (Figure 2c). The diagnosis of discoid lupus erythematosus 
(DLE) was confirmed. The patient received hydroxychloroquine 200 mg once 
a day, compound glycyrrhizin tablets (two tablets three times a day, containing 
150 mg glycyrrhizin, 210 mg monoammonium glycyrrhizinate, 150 mg amino-
acetic acid, and 150 mg methionine), and topical application of 0.1% tacrolimus 
cream once a day. The condition of the patient improved after 4 months of treat-
ment (Figure 2d and e).
3.3 Case 3. Neonatal lupus erythematosus
A 3-month-old female infant presented with a butterfly-like edematous erythe-
matosus on the center of her face, with raised border and scales (Figure 3a).
Due to the presence of scales on the lesion, a direct microscope examination 
with 16% potassium hydroxide (KOH), was done to rule out the fungal infection. 
However, the examination was not significant. In order to rule out congenital 
Figure 2. 
(a) A 38-year-old male showed erythema, papules, callus shells, and plaques on the left prefrontal region.  
(b) Dermoscopic evaluation of the lesions showed an erythematosus base interrupted by keratinization around 
the hair follicles and follicular keratotic plugging. (c) Histopathologic evaluation of the lesions revealed dilated 
follicular openings filled with cornified material, follicular plugging, a necrosed part of the stratum basale, and 
inflammatory cell infiltration of the perifollicular and shallow dermal layers, which indicated discoid lupus 
erythematosus (DLE) (HE stain, original magnification × 40). (d) After more than 4 months of treatment, the 
condition improved obviously. (e) Dermoscopic evaluation of the lesions showed an erythematosus scar instead 
of keratinization around the hair follicles, and follicular keratotic plugging.
Figure 3. 
(a) A 3-month-old female infant presented with butterfly-like edematous erythematosus on the center of 
her face, with raised border and scales. (b) After continuous treatment for 153 days with 0.03% tacrolimus 
cream once a day, and total glucosides of paeony capsules 300 mg once a day, the butterfly-like rash almost 
disappeared.
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syphilis, the Treponema pallidum particle agglutination assay (TPPA) and toluidine 
red unheated serum test (TRUST) tests were also done, with negative results. 
Finally, the autoimmune antibodies were examined. The report showed ANA (±), 
Anti-SSA (+++), and C3 and C4 were reduced. However, Anti-ds-DNA and rest of 
the anti-ENA examinations were not significant. The autoimmune antibodies of the 
patient’s mother were not significant. The report showed ANA (+), Anti-SSA (+++) 
and Anti-Ro-52 (+++). Based on the manifestations, the final diagnosis of neonatal 
lupus erythematosus (NLE) was confirmed. The patient was treated with topical 
application of 0.03% tacrolimus cream once a day and total glucosides of paeony 
capsules 300 mg once a day.
After continuous treatment for 153 days, the butterfly-like rash almost disap-
peared (Figure 3b). After following up for 5 years, the conditions of both the 
patient and her mother improved with no features of lupus erythematosus.
3.4 Case 4. Neonatal lupus erythematosus baby and her SCLE mother
A 3-month-old female infant presented with butterfly-like rash on the center of 
her face since birth (Figure 4a). The dermoscopy of the lesion showed perifollicular 
whitish halo and telangiectasias (Figure 4b). It was quite similar with the most 
common dermoscopic criteria of LE.
Meanwhile while examining the mother’s face, we found pink-red erythematous 
plaque on the center of her face (Figure 4c), which may get worse after sun expo-
sure. And also, we found red edematous coin shaped patch on the left side of her 
face. Dermoscopy of the skin lesion showed typical telangiectasias manifestations 
(Figure 4d).
The autoimmune antibodies examinations of the infant showed ANA (1:100), 
Anti-SSA (+), C3 and C4 were reduced. And her mother’s examination showed ANA 
(1:1000), Anti-SSA (+++), C3 and C4 were reduced. However, the ds-DNA and the 
rest of anti-ENA examinations were not significant.
The final diagnosis of the infant as neonatal lupus erythematosus (NLE), and 
her mother as SCLE were confirmed.
Figure 4. 
(a) A 3-month-old female infant presented with butterfly-like rash on the center of her face since birth. 
(b) Dermoscopy showed perifollicular whitish halo and telangiectasias with a pink-red background. (c) 
The mother’s face showed pink-red erythematous plaques on the center of her face, which may get worse 
after sun exposure. (d) Dermoscopy of the skin lesion showed typical telangiectasias manifestations with a 
pink-red background. (e) After 125 days follow up without medication, the baby’s butterfly-like rash almost 
disappeared. ( f) Dermoscopy showed the red background of lesion was lighter than initial performance. (g) 
After treatment for 125 days with 30 mg prednisone once a day, the skin lesion of the mother subsided. (h) 
Dermoscopy showed improved manifestations of telangiectasias.
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The infant was given total paeony glycoside orally, but her parents did not 
implement it to her actually. The mother was treated with 30 mg prednisone once 
a day and was recommended to protect the skin from excessive sun exposure. The 
butterfly like rash of the baby almost disappeared when the follow-up after 125 days 
(Figure 4e and f), and the results of immunological examination were within the 
normal range. The skin lesion of the mother subsided (Figure 4g and h) and the re-
examination of her autoimmune antibodies’ examinations showed ANA (1:1000), 
Anti-SSA (+++) with no symptoms.
4. Discussion
Linear cutaneous lupus erythematosus (LCLE) is rare, and the skin lesions are 
mostly distributed along the Blaschko lines. The Blaschko lines, which was first 
described by and named by Blaschko in 1901, is the special lines on the surface of 
the human body. On the back of the trunk, the Blaschko line is V-shaped across the 
spine, and S-shaped on the anterior and lateral skins of the trunk. It exists in the 
form of vertical stripes on the skin of extremities, and is turbine-like on the surface 
of the abdominal skin and spiral-like on the scalp. The schematic diagram of the 
division of the facial Blaschko line was proposed see [9] in 1994, and it has different 
distribution patterns in different parts of the face. Discoid lupus erythematosus 
(DLE) lesion distribute along the Blaschko line in two Japanese children with the 
onset age being 3 and 11 years and the lesions located in the right cheek, left lower 
jaw and left neck, respectively in 1998 [10]. The authors analyzed the previous 6 
cases and the current 2 cases, whereby they found that the 6 patients had an onset 
age of being smaller than 14 years, and that none of the patients had progressed into 
systemic lupus erythematosus. They argued that it might be a new subtype of lupus 
erythematosus, and proposed the name of linear cutaneous lupus erythematosus 
for DLE lesion with a linear configuration. In 1999 subsequently, an 8-year-old 
black boy with a lesion of LCLE along the Blaschko line in the right cheek and right 
chest, respectively see [11]; a 3-year-old Hispanic boy developed a lesion on his face 
and neck in 2002 see [12]. The lesion in our patient was located in the left forehead 
and left upper eyelid, which was formed S-shaped lesion, but was not distributed 
along the Blaschko line. This case was rather rarer and indicated that the skin lesion 
of LCLE was not necessarily distributed along the Blaschko line. In an adult case 
with linear, atrophic, plaque on left jaw and neck which did not follow the lines of 
Blaschko strictly [13]. But our case followed a reversed Blaschko lines (S shape line) 
on the left face.
As a matter of fact, the clinical presentations of DLE could be difficult to 
distinguish from other erythematous like patches and plaques. Thus, we highly 
recommend the use of non-invasive tool of dermoscopic technology to examine 
the details of skin lesions. The manifestations under dermoscopic findings of DLE 
could have erythematous base interrupted by prominent keratinization around the 
hair follicles and follicular keratotic plugging. According to the studies, follicular 
keratotic plug is one of the markers of discoid lupus erythematosus [14].
Another important method to confirm the diagnosis of DLE is histopathological 
examination. The typical features of DLE is follicular keratotic plugging, vacuolar 
alteration of the basal cell layer, thickening of the basement membrane, perivascu-
lar and periappendicular infiltration of the lymphocytes in the dermis.
Autoimmune antibodies such as Anti-Ds-DNA, ANA, ENA and immunoglobu-
lins plays an important role in the diagnosis of SLE patients. However, in most 
conditions, the positive rate of antibodies could be very low in DLE patients. And in 
some patients no any manifestations are seen except the skin lesions.
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SLE in children is fundamentally the same disease as in adults, with similar 
etiology, pathogenesis, clinical manifestations, and laboratory findings. However, 
it is generally accepted that children with SLE have greater disease severity and 
earlier accrual of disease damage than adults with SLE [15–19]. Worldwide, 
estimates of childhood-onset SLE incidence are between 0.3 and 2.2 per 100,000 
children-years, while prevalence rates range widely from 3.3 to 9.7 per 100,000 
children and adolescents, depending upon the population studied and its ethnic 
distribution [20–31].
Neonatal lupus is a rare syndrome that is associated with maternal antibodies 
to Ro/SSA, to La/SSB, and, much less frequently, to U1RNP. Infants develop erup-
tions characterized by erythematous arcuate patches or plaques with raised active 
margins shortly after birth. Congenital heart block is the most concerning compli-
cation of neonatal lupus. Following the birth of an infant with neonatal lupus, the 
risk for congenital heart block is increased with subsequent pregnancies [32]. Of 
note, treatment with hydroxychloroquine may decrease the risk of neonatal lupus 
(congenital heart block) in at-risk pregnancies [33].
The infant LE patients may derive the autoimmune antibodies from their mother 
in order to diagnose the neonatal lupus erythematosus. Thus, it is very important to 
examine the antibodies of the mother, who may also be a subclinical LE patient and 
need continuous follow-ups or managements.
For treatment, topical application of tacrolimus ointment is the most recom-
mended therapy. Except one SCLE patient who had significantly increase titers of 
ANA and Anti-SSA, we used mild moderate dose of prednisone, all other LCLE, 
DLE and NLE did not give systemic prednisone, instead with compound glycyrrhi-
zin tablets, or, total glucosides of paeony capsules which made from the extracts of 
traditional Chinese medicine. During our clinical practices, these medicines showed 
reliable efficiency and very few of side effect, with a favorable prognosis. In case 
4, the skin lesion of neonatal lupus erythematosus baby spontaneously alleviated, 
suggested that it can remission without disposal, accompanied the autoantibodies 
from her mother decreases. But long-term follow-up is still needed.
5. Conclusion
In order to confirm the special clinical cases of lupus, such as linear cutaneous 
lupus erythematosus, DLE, or neonatal lupus erythematosus, the characteristics of 
dermoscopy and autoimmune antibodies tests are important. In these cases, topical 
tacrolimus, oral compound glycyrrhizin or total paeony glycoside, or, hydroxychlo-
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